A new antiviral targeting the hepatitis B virus capsid protein
A new class of antiviral directed at HBV capsid protein
This study is testing a new treatment for people with chronic Hepatitis B that aims to better target the virus while reducing side effects, making it a potentially more effective option for managing the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Door Pharmaceuticals, LLC NIH-funded |
| Lab location | 1 site (Bloomington, United States) |
| Project ID | NIH-10816889 on NIH RePORTER |
What this research studies
This research focuses on developing a novel antiviral treatment for chronic Hepatitis B Virus (HBV) by targeting the virus's capsid protein. The approach involves creating reactive capsid assembly modulators (rCAMs) that can specifically bind to viral nucleic acids, enhancing the effectiveness of the treatment while minimizing side effects. By concentrating the reactive components near the viral DNA and RNA, this method aims to provide a more effective and potentially curative therapy for patients suffering from chronic HBV. The research is being conducted by Door Pharmaceuticals, which has a strong background in this area.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with chronic hepatitis B virus infection.
Not a fit: Patients who have not been diagnosed with chronic hepatitis B or those with acute hepatitis B may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a curative treatment for chronic hepatitis B, significantly improving patient outcomes.
How similar studies have performed: While the approach of using capsid assembly modulators is innovative, similar strategies targeting viral components have shown promise in other viral infections, indicating potential for success.
Where this research is happening
Bloomington, United States
- Door Pharmaceuticals, LLC — Bloomington, United States (Active)
Researchers
- Principal investigator: Nair, Smita — Door Pharmaceuticals, LLC
- Study coordinator: Nair, Smita
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.